Vijayaganapathi A, Mohanasrinivasan V
School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.
Probiotics Antimicrob Proteins. 2025 Jun 3. doi: 10.1007/s12602-025-10606-2.
Next-generation probiotics (NGPs) represent a promising advancement in microbial therapeutics, offering targeted and personalized interventions for various health disorders. Unlike traditional probiotics, NGPs focus on specific bacterial strains with enhanced functional properties, achieved through genetic engineering and next-generation sequencing technologies. Their applications span gastrointestinal disorders, metabolic syndromes, immune-related conditions, skin diseases, oral health, and animal well-being. NGPs contribute to gut microbiome modulation, metabolic regulation, and immune system enhancement, demonstrating therapeutic potential in clinical studies. Regulatory challenges persist, as NGPs fall under different legal classifications worldwide, necessitating rigorous safety assessments, including whole-genome sequencing to evaluate virulence and antibiotic resistance. Clinical trials continue to validate their efficacy in diverse conditions, emphasizing the need for standardized guidelines. Furthermore, novel probiotic delivery systems, including microdevices and targeted coatings, are being explored to improve bacterial viability and colonization in the gut. Identifying new probiotic strains with enhanced survival capabilities and elucidating their mechanisms of action remain critical for advancing probiotic science. Cost-effectiveness and commercialization of NGPs present opportunities for broader healthcare integration, with increasing research supporting their role in disease prevention and treatment. This review highlights the multifaceted potential of NGPs and the challenges that must be addressed for their successful implementation in modern healthcare.
下一代益生菌（NGPs）代表了微生物治疗领域一项有前景的进展，为各种健康疾病提供了有针对性的个性化干预措施。与传统益生菌不同，NGPs专注于具有增强功能特性的特定细菌菌株，这是通过基因工程和下一代测序技术实现的。它们的应用涵盖胃肠道疾病、代谢综合征、免疫相关病症、皮肤病、口腔健康以及动物健康。NGPs有助于调节肠道微生物群、调节代谢和增强免疫系统，在临床研究中显示出治疗潜力。监管挑战依然存在，因为NGPs在全球范围内属于不同的法律分类，需要进行严格的安全性评估，包括全基因组测序以评估毒力和抗生素耐药性。临床试验继续在各种情况下验证其疗效，强调需要标准化指南。此外，正在探索新型益生菌递送系统，包括微器件和靶向涂层，以提高细菌在肠道中的生存能力和定植能力。识别具有增强生存能力的新益生菌菌株并阐明其作用机制对于推进益生菌科学仍然至关重要。NGPs的成本效益和商业化提供了更广泛医疗保健整合的机会，越来越多的研究支持它们在疾病预防和治疗中的作用。本综述强调了NGPs的多方面潜力以及在现代医疗保健中成功实施它们必须解决的挑战。
